---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-245815"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-10-22T23:59:59+00:00"
generated_at: "2026-05-17T02:41:43.300871+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jazz settles patent litigation with Avadel; grants Lumryz license, pays $90M

## Summary
- Jazz pays $90M lump sum to Avadel and waives certain prior royalties to settle all litigation.
- Avadel gets immediate license for Lumryz in narcolepsy; license for other indications starts March 1, 2028.
- Avadel will pay 3.85% royalty on narcolepsy Lumryz sales (starting Oct 1, 2025) and 10% on other indications.
- Jazz expects ~$90M pre-tax charge in Q3 2025, funded with cash on hand.
- Jazz denies all alleged wrongdoing; both parties dismiss pending legal proceedings.

## SEC filing metadata
- accession: 0001193125-25-245815
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-10-22T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312525245815/0001193125-25-245815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312525245815/d65147d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-245815
- JSON: https://secwatch.observer/filing/0001193125-25-245815.json
- Plain text: https://secwatch.observer/filing/0001193125-25-245815.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.